INNOGEN-B (02591) saw its shares climb more than 18% in early trading, though they later pared gains to trade up 10.23% at HK$7.815, with turnover reaching HK$23.282 million.

Driving the move, INNOGEN announced on August 3 that on July 27, 2026, two of its contract manufacturing sites in China passed a compliance inspection by Brazil's National Health Surveillance Agency (ANVISA) under the Pharmaceutical Inspection Co-operation Scheme (PIC/S) GMP standards, and have received the relevant GMP certificates.

The company stated that obtaining the PIC/S GMP certificates confirms that the drug substance and finished product manufacturing and quality management systems at the contract sites meet PIC/S GMP standards. This achievement is expected to further expand the commercial production capacity for INNOGEN's Suzhou Pegloticase Alpha injection and accelerate the drug's registration and commercialization process within PIC/S member countries.